Quick Answer
Janux Therapeutics, Inc. reported Net Income of -$113.62 million for fiscal year 2025.
Janux Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$113.62M | -64.7% |
| 2024 | -$68.99M | -18.4% |
| 2023 | -$58.29M | +7.6% |
| 2022 | -$63.06M | -93.0% |
| 2021 | -$32.67M | -381.6% |
| 2020 | -$6.78M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$24.31M | +13.4% | +28.2% |
| June 30, 2025 | -$33.86M | -468.2% | -44.0% |
| March 31, 2025 | -$23.51M | -59.3% | +16.2% |
| September 30, 2024 | -$28.06M | -142.6% | -370.9% |
| June 30, 2024 | -$5.96M | +66.0% | +59.6% |
| March 31, 2024 | -$14.76M | +15.5% | -27.6% |
| September 30, 2023 | -$11.57M | +30.7% | +33.9% |
| June 30, 2023 | -$17.51M | -3.7% | -0.3% |
- Janux Therapeutics, Inc. showed a decrease of -64.7% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Janux Therapeutics, Inc.’s net income has declined by 1574.9% (from -$6.78 million to -$113.62 million).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: